#ASCVD
LightNews LightNews
accintouch.bsky.social
ADHERE-#ASCVD: Digital outreach through a variety of formats may improve short-term statin refill consistently across a broad age range.

🔗 https://bit.ly/4epdcdR #ScientificSessions26 #JACC #CardioSky
November 8, 2026 at 6:26 PM
accintouch.bsky.social
ZEUS: Anti-inflammatory therapy targeting IL-1β with ziltivekimab did not lower risks of cardiovascular events compared with placebo in high-risk patients with #ASCVD, chronic kidney disease and systemic inflammation.

Read more: https://bit.ly/4Ail2yv #ScientificSessions26 #CardioSky
November 7, 2026 at 4:00 PM
medpagetoday.com
Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with ASCVD, CKD, and CV inflammation.
https://www.medpagetoday.com/meetingcoverage/aha/123773
Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD
ZEUS did show IL-6 reduction so inflammation remains a key treatment target, expert says
www.medpagetoday.com
November 9, 2026 at 8:54 PM
rheumcat.bsky.social
⭐ Abs 1334 Guerra Sayre

📊 PsD cohort n=6599

🔎 estimated 10yr ASCVD risk and its association with time to MACE

#ACR26
November 9, 2026 at 2:31 PM
lnkd.in/p/dW9JHH3m
#ascvd #scientificsessions26 | American College of Cardiology
Anti-inflammatory therapy targeting interleukin-6 (IL-1β) with ziltivekimab (a monoclonal antibody) did not lower risks of cardiovascular events compared with placebo in high-risk patients with athero...
lnkd.in
November 9, 2026 at 1:48 AM
rickmcguire.bsky.social
Best of: Cannabis use is associated with increased odds of atherosclerotic cardiovascular disease, even in young people without standard risk factors. bit.ly/4sMhxhd
AHA: Cannabis Use Linked to Increased Odds of Atherosclerotic CVD
THURSDAY, Nov. 5, 2026 (HealthDay News) -- Cannabis use is associated with increased odds of atherosclerotic cardiovascular disease (ASCVD) in specific subgroup
bit.ly
November 7, 2026 at 3:00 PM
inlightbio.bsky.social
Scale check: 544,103 US adults with ASCVD on prior statins (64,421 started Repatha vs 479,682 ezetimibe) in AJPC. MI HR 0.80 (0.70–0.91). With baseline LDL (n=225,048), 4-year MI risk was 5.88% vs 7.76%. Real-world complement to trials, still observational. #pharma #biotech
November 8, 2026 at 6:14 PM
thelancetendo.bsky.social
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular disease prevention thelancet.com/journals/lan...
#LDL #cholesterol #atherosclerotic #cardiovascular disease #ASCVD #statins #ezetimibe #PCSK9 inhibitors

#MedSky #EndoSky #CardioSky
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention
This TimeCapsule reviews the major transformations in lipid metabolism and cardiovascular disease prevention during the first quarter of the 21st century and their impact on clinical practice. From la...
thelancet.com
November 8, 2026 at 1:01 PM
rickmcguire.bsky.social
Cannabis use is associated with increased odds of atherosclerotic cardiovascular disease, even in young people without standard risk factors. bit.ly/4sMhxhd
AHA: Cannabis Use Linked to Increased Odds of Atherosclerotic CVD
THURSDAY, Nov. 5, 2026 (HealthDay News) -- Cannabis use is associated with increased odds of atherosclerotic cardiovascular disease (ASCVD) in specific subgroup
bit.ly
November 5, 2026 at 5:36 PM
medicalxpress.com.web.brid.gy
AHA: Cannabis use linked to increased odds of atherosclerotic cardiovascular disease
Cannabis use is associated with increased odds of atherosclerotic cardiovascular disease (ASCVD) in specific subgroups, including never-smokers, women and young adults without traditional risk factors, according to a study presented at the American Heart Association Scientific Sessions 2026, held from Nov. 6 to 9 in Chicago.
medicalxpress.com
November 5, 2026 at 8:34 PM
vindicomeded.bsky.social
This activity will improve your knowledge, skills, and performance in #ASCVD management. Participate now: https://www.healio.com/cme/lipidcme/assessing-cvd-risk/20260806/lipid-management-in-an-era-of-evolving-evidence?utm_source=Bluesky&utm_medium=post&utm_campaign=H704
November 3, 2026 at 12:31 PM
aspcardio.bsky.social
Advance your approach to residual CV risk in ASCVD & CKD with our free online Master Class. Review therapies, test your knowledge, earn CME, and work toward a Master Class badge.

Explore the activity: https://www.healio.com/cme/cardiology/inflammation-in-focus

#CardioHealth #MedicalEducation #ASPC
Inflammation in Focus: A Master Class on Residual Cardiovascular Risk in ASCVD and CKD
In this Master Class, Dr. Michael Blaha discusses the role of cardiovascular inflammation in atherosclerosis and reframing atherosclerotic cardiovascular disease as both a lipid-driven and inflammatory disease.
www.healio.com
November 2, 2026 at 11:00 PM
cardiologyadvisor.bsky.social
Veterans with atherosclerotic #cardiovascular disease who participate in a personalized health coach program achieve clinically meaningful reductions in low-density lipoprotein #cholesterol.

#ASCVD

https://bit.ly/3WIYSH0
Tailored Health Coach Intervention Associated With Decreased LDL-C in Veterans
A tailored health coach intervention significantly reduces low-density lipoprotein cholesterol levels in veterans with cardiovascular disease.
www.thecardiologyadvisor.com
November 3, 2026 at 4:43 PM
med-office-j.bsky.social
【65歳以上のスタチン中止で入院リスク高？/Lancet HL】Nov.02

英国GP患者DB、65歳以上でスタチン中止の65,727例と継続131,453例中、IPTW後61,080例と 136,100例比較 [55%にASCVD既往] ——

・スタチン「中止」で「継続」に比べ、1年間「全入院」の部分分
　布HRは1.22の有意高値。NNHは「27」（「死亡」は報告なし）。
・「中止」に伴う「全入院」HRは [なぜか]、ASCVD既往例 [1.21]
　よりも1次予防例 [1.30] の方が有意に高。

全文🔗　qr.paps.jp/948bD
Efficacy and safety of statin discontinuation in patients 65 years and older according to frailty status: a population-wide retrospective cohort study in England using Clinical Practice Research Datal...
In older adults, statin discontinuation was associated with an increased risk of hospitalisation, although this association diminished with increasing frailty. These findings could inform individualis...
qr.paps.jp
November 3, 2026 at 1:24 AM
jantonioglopezmd.bsky.social
High Prevalence of Premature ASCVD Found in Arab American Patients www.thecardiologyadvisor.com/news/ascvd-c...
High Prevalence of Premature ASCVD Found in Arab American Patients
Arab American adults experience a high prevalence of atherosclerotic cardiovascular disease and related cardiometabolic risk factors.
www.thecardiologyadvisor.com
October 29, 2026 at 3:43 PM
jaccjournals.bsky.social
Could combining LDL-C, Lp(a), and hsCRP refine #ASCVD risk prediction across ethnicities? Annink et al. investigates in the multiethnic HELIUS cohort. NEW in #JACC: https://bit.ly/3WdQP4T

#CardioSky #Cardiology #Cholesterol
October 30, 2026 at 1:15 PM
thelancetendo.bsky.social
Published in @eclinicalmed.bsky.social

Comparative effectiveness of #lipid-lowering therapies for primary #cardiovascular prevention: a network meta-analysis of randomised controlled trials www.thelancet.com/journals/ecl...
#ASCVD
#OpenAccess
#MedSky #EndoSky #CardioSky
Comparative effectiveness of lipid-lowering therapies for primary cardiovascular prevention: a network meta-analysis of randomised controlled trials
Benefit in primary prevention tracked statin intensity rather than drug class. Evolocumab added to a statin conferred further benefit over that statin, whereas EPA and fibrates did not, and bempedoic ...
www.thelancet.com
October 29, 2026 at 8:32 AM
snacknutrition.bsky.social
"For individuals with #ASCVD who are at very high #risk of ASCVD events, the LDL-C #goal should be less than 55 mg/dL for secondary #prevention of cardiac #events. In general, lower #LDL is better, especially for #people at increased risk for a heart attack or #stroke"
#health #diet #nutrition
October 27, 2026 at 11:25 AM
cardiologyadvisor.bsky.social
The prevalence of #cardiometabolic conditions increases progressively with #age among Arab American adults, underscoring the need for early preventive interventions.

https://bit.ly/4Bxycch
High Prevalence of Premature ASCVD Found in Arab American Patients
Arab American adults experience a high prevalence of atherosclerotic cardiovascular disease and related cardiometabolic risk factors.
www.thecardiologyadvisor.com
October 28, 2026 at 8:38 PM
tctmd.bsky.social
Pulmonary embolism may have a connection with atherosclerotic cardiovascular disease—a recent analysis of US data shows that PE-attributed deaths are on the rise among ASCVD patients, especially for younger adults and racial/ethnic minority groups. https://bit.ly/4e0H4wZ
US Data Support Link Between Pulmonary Embolism, ASCVD
Deaths tied to PE are on the rise in ASCVD patients, especially in younger adults and in underserved racial/ethnic groups.
bit.ly
October 27, 2026 at 7:02 PM
womenasone.bsky.social
Our partnership with Radcliffe Cardiology expands access to expert-led education across four clinical topic areas through #CLIMB2026.

Together, we're helping women physicians build clinical expertise & advance cardiovascular care.

Learn more: womenasone.org/lates...

#CardioSky
Access high-quality clinical education - ASCVD Prevention: Lipid Management - Al in Cardiovascular Medicine - Cardiorenal Metabolic Health - Transthyretin Amyloidosis
October 26, 2026 at 3:00 PM
aspcardio.bsky.social
Bring Residual Cardiovascular Risk in ASCVD and CKD into focus in this free online Master Class. Earn free CE and collect points as you learn. Your points add up toward a Master Class badge.

Start learning: https://www.healio.com/cme/cardiology/inflammation-in-focus

#CardioHealth #ResidualRisk
Inflammation in Focus: A Master Class on Residual Cardiovascular Risk in ASCVD and CKD
In this Master Class, Dr. Michael Blaha discusses the role of cardiovascular inflammation in atherosclerosis and reframing atherosclerotic cardiovascular disease as both a lipid-driven and inflammatory disease.
www.healio.com
October 26, 2026 at 9:00 PM
vindicomeded.bsky.social
Review key recommendations for primary and secondary prevention of #ASCVD with this #CE activity: https://www.healio.com/cme/lipidcme/assessing-cvd-risk/20260806/lipid-management-in-an-era-of-evolving-evidence?utm_source=Bluesky&utm_medium=post&utm_campaign=H704
October 25, 2026 at 2:02 PM
thebiotechtimes.bsky.social
Monte Rosa's NEK7 degrader normalised key cardiovascular inflammation markers to healthy-volunteer levels in obese, high-risk subjects. Phase 1 data on MRT-8102 suggest a potential route to ASCVD risk reduction.
Monte Rosa MRT-8102 Phase 1 data show ASCVD biomarker normalisation
Monte Rosa's NEK7-directed molecular glue degrader cut key cardiovascular inflammation markers to healthy-volunteer levels in obese, high-risk subjects.
thebiotechtimes.com
October 24, 2026 at 2:00 PM
jantonioglopezmd.bsky.social
www.tctmd.com/news/us-data...
US Data Support Link Between Pulmonary Embolism, ASCVD
Deaths tied to PE are on the rise in ASCVD patients, especially in younger adults and in underserved racial/ethnic groups.
www.tctmd.com
October 23, 2026 at 2:15 PM